Polopiryna Complex powder for oral solution (500mg + 2 mg + 15.58 mg) x 8 sachets

Directions for use: use w/o doctor's instructions.
See package insert for detailed directions for use.

Storage: Store at ambient temperature

Acetylsalicylic Acid

Zakłady Farmaceutyczne Polpharma S.A.

Zakłady Farmaceutyczne Polpharma S.A.,
19 Pelplińska street,
83-200 Starogard Gdański,
PL

The product should not be used in patients taking oral antidiabetic drugs of the sulfonylurea group, due to the risk of increased hypoglycemic effect, and in patients taking antidnausea drugs. Caution should be exercised when using the product in patients with renal impairment and chronic renal failure. In patients with juvenile rheumatoid arthritis and/or systemic lupus erythematosus and impaired liver function, the product should be used with caution as salicylate toxicity is increased; liver function should be monitored in these patients. Taking the product at the lowest effective dose for the shortest period necessary to relieve symptoms reduces the risk of side effects. The product should be discontinued 5 to 7 days before a planned surgical procedure, due to the risk of prolonged bleeding time both during and after surgery. Caution should be exercised when used with methotrexate at doses of less than 15 mg per week, due to an increase in the toxic effects of methotrexate on the bone marrow. Concomitant use with methotrexate in doses greater than 15 mg per week is contraindicated. Use with caution in cases of: uterine hemorrhages, excessive menstrual bleeding, IUD use, hypertension and heart failure. Alcohol should not be consumed during treatment, due to the increased risk of damage to the gastrointestinal mucosa. The drug may affect female fertility. The drug may cause cross-sensitivity; patients sensitive to a particular antihistamine may also be sensitive to others. The product should be used with caution in patients with occlusive vascular disease (including Raynaud's disease). The product should be used with caution in patients prone to urinary retention or with glaucoma. The benefit/risk ratio should be considered in the following cases: renal or pulmonary disorders, bronchitis or bronchial dilatation, cardiovascular disorders (bradycardia, idiopathic orthostatic hypotonia), cerebral arteriosclerosis, pancreatitis, scarring peptic ulcer, duodenal pyloric obstruction, anemia, thyroid disease, in sedation-sensitive patients and patients with epilepsy, as it may cause interactions or affect the effect of the drugs they are taking. Patients taking tricyclic antidepressants, maprotiline or other drugs with anticholinergic effects, or chlorphenamine, should notify their doctor immediately if they experience gastrointestinal distress due to the risk of paralytic intestinal obstruction. Patients should be advised to contact their doctor if symptoms persist and that other products containing the same active ingredients should not be used at the same time. Use in elderly patients. Due to the content of phenylephrine and chlorphenamine in the formulation, the drug product should be used with caution in elderly patients. In particular, it may cause bradycardia and decreased cardiac flow. Blood pressure should be monitored, especially in elderly patients with heart disease. Elderly patients are more likely to experience: dizziness, sedation, confusional states, hypotension, and paradoxical reaction, characterized by hyperactivity; elderly patients are more susceptible to anticholinergic effects of antihistamines, manifested, for example, by dry mouth and urinary retention. If the described side effects persist or if they worsen, it may be necessary to discontinue treatment. Warnings regarding excipients. The product contains 2182 mg of sucrose in each sachet. Patients with rare hereditary disorders related to fructose intolerance, glucose-galactose malabsorption syndrome or saccharase-isomaltase deficiency should not take the drug product. This should be taken into account in patients with diabetes. The product, due to its sulfite content, can rarely cause severe hypersensitivity reactions and bronchospasm. The product contains less than 1 mmol (23 mg) of sodium per sachet, that is, the product is considered "sodium free."